Systematic review and network meta-analysis of the effects of plant active substance on quality of life in breast cancer patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41394145/
https://www.crd.york.ac.uk/prospero/, identifier CRD420251006422.
Network meta-analysis shows plant bioactives improve quality of life in breast cancer, with Withania somnifera ranking highest for overall QoL, fatigue, pain, nausea, and functional outcomes, supporting adjunctive therapeutic potential.
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41422321/
Despite improvements in surgical techniques, advances in delivery of radiation therapy, and development of therapies with central nervous system (CNS) activity, the presence of CNS metastases from breast cancer is...
This review outlines priorities for breast cancer CNS metastases, including screening strategies, optimal sequencing of local and systemic therapies, leptomeningeal disease management, and innovative, collaborative clinical trials to improve outcomes.
How to prevent and treat cardiovascular diseases in people living with breast cancer? Recent advances - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41358433/
Breast cancer treatment has improved in recent decades, meaning that, in more economically developed countries, people living with breast cancer (PLBC) and breast cancer survivors (BCS) face a decreasing mortality...
Breast cancer survivors face heightened cardiovascular risk from shared disease mechanisms and treatment toxicities. Emerging prevention strategies, early detection of subclinical injury, and long-term surveillance are essential to reduce CTR-CVT burden.
Phase Ib trial shows ALECSAT adoptive cell therapy plus carboplatin–gemcitabine is safe and yields promising responses in metastatic TNBC, with higher infused CD8+ T-cell doses correlating with longer disease control.
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Caused by Pola-R-CHOP: A Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41267725/
Chemotherapy regimens, especially for haematologic malignancies, have been increasingly implicated in drug reactions with eosinophilia and systemic symptoms (DRESS) syndrome. We present a case of DRESS syndrome in a patient...
DLBCL patient on pola-R-CHOP developed severe rash and systemic illness diagnosed as DRESS; steroids led to improvement despite CMV reactivation complicating management. Highlights need for early recognition in oncology patients.